Dako and OSI Pharmaceuticals will collaborate on developing a companion diagnostic for one of OSI’s cancer therapies. The test is intended to identify patients more likely to benefit from a specific treatment.
The partnership will draw on Dako's experience in cancer diagnostics and OSI’s background in developing and commercializing drugs. Dako says that this alliance is in line with its ongoing strategy to combine its strengths with pharmaceutical companies to leverage its diagnostic platform, pharmDx™.
“Linking a drug with a diagnostic test is what you can call a triple-win situation,” according to Lars Holmkvist, CEO and president of Dako Denmark. “Most importantly, the patient will receive relevant therapy from the start instead of a trial-and-error medication. Secondly, the pharmaceutical company may develop even more innovative and improved cancer therapies. Thirdly, Dako itself will continue to provide gold-standard companion diagnostics to the market.